Abstract Background Immune checkpoint inhibitors (ICIs) showed antitumor activity for
recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). However …

Background We aimed to investigate the efficacy and tolerability of sorafenib combined with
cisplatin and 5-fluorouracil (5-FU) in patients with recurrent or metastatic nasopharyngeal …

Immune‐checkpoint inhibitors improve the survival of head and neck squamous cell
carcinoma (HNSCC) patients. Although recent studies have demonstrated that the tumor …

Background: Resistance to 5-fluorouracil (5-FU) is a major obstacle in treating oral
squamous cell carcinoma (OSCC). However, little is known about apoptosis resistance …

The measurement of patient-reported outcome measures (PROMs) following head and neck
cancer (HNC) has the capacity to substantially enhance the care of patients and their care …

Chemoresistance remains a challenge in the effective treatment of solid tumors, including
oral squamous cell carcinoma (OSCC). Mitochondrial dynamics and autophagy have …

Locoregional disease recurrence or development of a second primary cancer after definitive
radiotherapy for head and neck cancers remains a treatment challenge. Reirradiation …

Background: Head and neck squamous cell carcinomas are the sixth most common
malignant tumors worldwide. Tongue squamous cell carcinoma is a common malignant …

Purpose: The goals of this study were to investigate the clinical activity, safety, and
biomarkers of dacomitinib, an irreversible tyrosine kinase inhibitor of EGFR, HER2, and …

Purpose: We investigated whether vandetanib, an inhibitor of the tyrosine kinase activities of
vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor …